 SALT LAKE CITY, Dec. 4, 2020 PRNewswire -- Lipocine Inc. NASDAQ: LPCN, a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration FDA has informed the Company that it is continuing to work... 